FacebookTwitterGoogle+RedditEmail

Big Pharma Has A Rare Week

The sound you hear is Pharma swinging from the rafters. Two news stories this week may reinfuse revenue streams in an industry whose blockbuster pill “bubble” has burst.  As Lipitor, Seroquel, Zyprexa, Singulair, Concerta and several other drugs have lost patent protection, Pharma is shedding both employees and ad campaigns. WebMD, the voice of Pharma on the Web, announced it would cut 250 positions in December and medical journals like the Journal of the American Medical Association (JAMA) and New England Journal of Medicine are noticeably thinner without the Pharma ads that have leavened them for years.

Vitamin D and calcium will not protect older women from fractures, a government task force reported this week, in the Annals of Internal Medicine. The U.S. Preventive Services Task Force “recommends against daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primary prevention of fractures” and  also recommends that older women, and younger ones with risk factors, be screened for osteoporosis.

While the report does not recommend expensive drugs or seem to be penned by Pharma consultants, its message is still good news for Pharma whose anti-osteoporosis drugs carried it through the 2000s.  “Don’t rely on just Vitamin D and calcium” and “get a bone scan!” were the marketing messages of the bone drugs Boniva, Fosamax and Actonel.

According to published reports, Merck, who launched the bone drug category with its Fosamax, single handedly initiated the “bone scan” craze foisted on middle aged and older women, including setting up a bone “institute” to secure Medicare reimbursement for the scans which were driving Fosamax sales.

Pharma even created the term “osteopenia”–at risk of osteoporosis–to sell the now discredited bone drugs, which are linked to esophageal cancer, osteonecrosis of the jaw, irregular heart beat, pain and actually causing fractures. Subsequent medical reports found the heavily marketed bone scans only benefit 10 percent of women who get them.

In more good news for Pharma this week, Genentech’s drug for allergic asthma, Xolair, co-marketed with Novartis, was trumpeted as having a new possible indication of treating patients with chronic hives or chronic idiopathic urticaria, reported the New York Times. If approved for the new indication, chronic idiopathic urticaria will likely became a major U.S. health problem to be advertised on TV like restless legs syndrome. Ka-ching.

Genetically engineered drugs like Xolair (called monoclonal antibodies) cost as much as $20,000 a year and cause TB, cancers and super infections according to their labels because they suppress the immune system. Xolair was investigated by the FDA for links to heart attack and stroke and 77 people who took Xolair had life-threatening allergic responses in a year and a half, according to FDA reports.

Some of the clinical tests to determine Xolair’s safety were conducted at Vivra which was investigated twice by the FDA for procedural irregularities. Trials of Xolair and at least seven other drugs were corrupted by protocol violations and outright falsifications, according to a former clinical research subinvestigator who worked at the facility. San Mateo, Calif.-based Vivra Asthma & Allergy was the nation’s largest respiratory disease physician practices until a merger with Lakewood, Colo.-based Gambro in 1997 and with El Segundo, Calif.-based DaVita in 2005.

There is even a genetically engineered monoclonal antibody drug called Prolia to treat osteoporosis that costs $1,650 a year now that we know Vitamin D and calcium don’t work.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

June 20, 2018
Henry Giroux
Trump’s War on Children is an act of State Terrorism
Bill Hackwell
Unprecedented Cruelty Against Immigrants and Their Children
Paul Atwood
“What? You Think We’re So Innocent?”
Nicola Perugini
The Palestinian Tipping Point
K.J. Noh
Destiny and Daring: South Korean President Moon Jae-In’s Impossible Journey Towards Peace
Gary Leupp
Jeff Sessions and St. Paul’s Clear and Wise Commands
M. G. Piety
On Speaking Small Truths to Power
Dave Lindorff
Some Straight Talk for Younger People on Social Security (and Medicare too)
George Wuerthner
The Public Value of Forests as Carbon Reserves
CJ Hopkins
Confession of a Putin-Nazi Denialist
David Schultz
Less Than Fundamental:  the Myth of Voting Rights in America
Rohullah Naderi
The West’s Over-Publicized Development Achievements in Afghanistan 
Dan Bacher
California Lacks Real Marine Protection as Offshore Drilling Expands in State Waters
Lori Hanson – Miguel Gomez
The Students of Nicaragua’s April Uprising
Russell Mokhiber
Are Corporations Behind Frivolous Lawsuits Against Corporations?
Michael Welton
Infusing Civil Society With Hope for a Better World
June 19, 2018
Ann Robertson - Bill Leumer
We Can Thank Top Union Officials for Trump
Lawrence Davidson
The Republican Party Falls Apart, the Democrats Get Stuck
Sheldon Richman
Trump, North Korea, and Iran
Richard Rubenstein
Trump the (Shakespearean) Fool: a New Look at the Dynamics of Trumpism
Kevin Zeese - Margaret Flowers
Protect Immigrant Rights; End the Crises That Drive Migration
Gary Leupp
Norway: Just Withdraw From NATO
Kristine Mattis
Nerd Culture, Adultolescence, and the Abdication of Social Priorities
Mike Garrity
The Forest Service Should Not be Above the Law
Colin Todhunter
Pro-GMO Activism And Smears Masquerade As Journalism: From Seralini To Jairam Ramesh, Aruna Rodrigues Puts The Record Straight
Doug Rawlings
Does the Burns/Novick Vietnam Documentary Deserve an Emmy?
Kenneth Surin
2018 Electioneering in Appalachian Virginia
Nino Pagliccia
Chrystia Freeland Fails to See the Emerging Multipolar World
John Forte
Stuart Hall and Us
June 18, 2018
Paul Street
Denuclearize the United States? An Unthinkable Thought
John Pilger
Bring Julian Assange Home
Conn Hallinan
The Spanish Labyrinth
Patrick Cockburn
Attacking Hodeidah is a Deliberate Act of Cruelty by the Trump Administration
Gary Leupp
Trump Gives Bibi Whatever He Wants
Thomas Knapp
Child Abductions: A Conversation It’s Hard to Believe We’re Even Having
Robert Fisk
I Spoke to Palestinians Who Still Hold the Keys to Homes They Fled Decades Ago – Many are Still Determined to Return
Steve Early
Requiem for a Steelworker: Mon Valley Memories of Oil Can Eddie
Jim Scheff
Protect Our National Forests From an Increase in Logging
Adam Parsons
Reclaiming the UN’s Radical Vision of Global Economic Justice
Dean Baker
Manufacturing Production Falls in May and No One Notices
Laura Flanders
Bottom-Up Wins in Virginia’s Primaries
Binoy Kampmark
The Anguish for Lost Buildings: Embers and Death at the Victoria Park Hotel
Weekend Edition
June 15, 2018
Friday - Sunday
Dan Kovalik
The US & Nicaragua: a Case Study in Historical Amnesia & Blindness
Jeremy Kuzmarov
Yellow Journalism and the New Cold War
Charles Pierson
The Day the US Became an Empire
FacebookTwitterGoogle+RedditEmail